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Abstract
Forty-five patients with acute leukemia were compared on cellular immunity measures versus
prognosis. The patients were treated according a multicombination therapy protocol. The purified
protein derivative (PPD) test and dinitrochlorobenzene (DNCB) test on admission indicated low
positive percentages. In acute non-lymphocytic leukemia (ANLL) patients, the 50% survival dura-
tions were 11 months in the PPD positive group and 6 months in the PPD negative group. In acute
lymphocytic leukemia (ALL) patients, the 50% survival durations were 21 months in the PPD
positive group and 13 months in the PPD negative group. Peripheral lymphocyte blastogenesis by
phytohemagglutinin (PHA) stimulation was examined at various clinical stages. The stimulation
indices were generally low, and no correlation was found between the PHA test and clinical stages.
These cellular immunity measures appeared to reflect one aspect of the clinical condition in acute
leukemia patients, and further studies are needed for predicting prognosis.
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Abstract. Forty-five patients with acute leukemia were compared
on cellular immunity measures versus prognosis. The patients were
treated according a multicombination therapy protocol. The purified
protein derivative (PPD) test and dinitrochlorobenzene (DNCB) test on
admission indicated low positive percentages. In acute non-lympho-
cytic leukemia (ANLL) patients, the 50% survival durations were 11
months in the PPD positive group and 6 months in the PPD negative
group. In acute lymphocytic leukemia (ALL) patients, the 50% survi-
val durations were 21 months in the PPD positive group and 13 months
in the PPD negative group. Peripheral lymphocyte blastogenesis by
phytohemagglutinin (PHA) stimulation was examined at various clini-
cal stages. The stimulation indices were generally low, and no cor-
relation was found between the PHA test and clinical stages. These
cellular immunity measures appeared to reflect one aspect of the clini-
cal condition in acute leukemia patients, and further studies are need-
ed for predicting prognosis.
Many studies have been conducted recently on the relationship between the
clinical course in malignant diseases and cellular immunity. Most of these
studies have been on the correlation between tumor regression and prognosis in
solid tumors and Hodgkin's disease (1-5). Few reports have dealt with immuno-
competence in acute leukemia (6-8), as its clinical manifestations change rapidly
during various stages of chemotherapy and prognosis is markedly affected by
sophisticated leukemia treatment. As reported previously (9), we have attained
a high rate of complete remission and a longer survival duration using newly
developed agents and a protocol of combined chemotherapy.
The purpose of this study was to examine changes in cellular immunity
during the clinical course of acute leukemia by the delayed hypersensitivity skin
tests and by the peripheral lymphocyte blastogenesis response to stimulation with
phytohemagglutinin to predict prognosis (10).
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MATERIALS AND METHODS
Forty-five patients treated from September 1973 to July 1975 in our clinic
were evaluated. All patients were cared and followed-up until death or June
1976. The diagnoses were as follows: 31 patients with acute non-lymphocytic
leukemias (ANLL), including 18 acute myelogenous leukemias (AML), 6 acute
promyelocytic leukemias (APL) and 7 monocytic leukemias (MoL) and 14 pa-
tients with acute lymphocytic leukemias (ALL). ANLL and ALL were separated
in the study because the clinical responses to chemotherapy and prognoses were
apparently different in each group. Age and sex distributions are shown in
Table 1.
TABLE 1. SEX AND AGE DISTRIBUTIONS OF PATIENTS OF THE ANLL
AND ALL GROUPS
Sex Age range
ANLL
ALL
Male
19
10
Female
12
4
15-19
6
5
20-29
4
5
30-39
10
2
40-49
4
o
50-59
6
60-66
Therapy. Intensive anti-leukemic chemotherapy was administered in cycles
of four consecutive days followed by a pause of 7 to 14 days until the remission
criteria were satisfied. The treatment protocol of ANLL and ALL is summa-
rized in Table 2. The details of treatment were previously reported (9).
TABLE 2. PROTOCOLS OF CHEMOTHERAPY IN ANLL AND ALL
I. Remission induction therapy
Combination used: NADP, NAMP, NDMP and NVMP.
(N) Neocarzinostatin-0.04-0.05mg/kg, i.v.drip infusion (four days)
(Al Cytosine arabinoside-I. 2-1. 5 mg/kg, i. v. drip infusion (four days)
(D) Daunomycin--O. 6-0. 7mg/kg, i. v. push (four days)
(M) 6-MP-riboside-5. 0-5.5 mg/kg, i. v. push (four days)
tV) Vincristine-0.04-0.06mg/kg, i.v. push (the first day)
(P) Prednisolone-O. 8-1. 0 mg/kg, i. V. drip infusion (four days)
II. Consolidation therapy
One course or two courses were administered of the same combination chemotherapy
shown in I.
III. Cyclic maintenance therapy
Each drug was given in 4 week cycles.
6-MP-2 mg/kg/day, p. o.
Cyclophosphamide-2mg/kg/day, p. O.
Methotrexate-O. 05 mg/kg/day, p. O.
Purified protein derivative (PPD) test. Intermediate strength PPD (Nippon
BCG Company, Tokyo) was used in the investigation. The sites of injections
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were rotated every month to different regions of the forearm and upperarm
to check the PPD reactivity. Criteria of positive reactivity were erythema and
induration of more than 5mm mean diameter.
Dinitrochloroben;;::ene (DNCB) test. DNCB (Ishizu Pharmaceutical Company,
Tokyo) was dissolved with acetone. This solution at 0.1 ml containing 2000 fig of
DNCB was sprayed on the shoulder, allowed to dry and covered. Two weeks
later challenge doses of 100 pg and 50 fig were applied on the forearm, and the
reactions were interpreted as positive or negative 2 days later. Positive criteria
were defined as induration and erythema with or without vesiculation (3).
Lymphocyte blastogenesis by phytohemagglutinin (PHA) stimulation. Venous
blood was drawn from patients at various clinical conditions when the periph-
eral smears showed no leukemic cells in leukocyte differential counts. The
method for evaluating blastogenesis was modified from the report of Pellegrino
et al. (11), as shown in Fig. I. Heparinized whole blood at 0.05ml was suspended
in 2ml of culture medium containing RPMI-1640 and 20% fetal calf serum.
Incubation
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Fig. 1. Method of lymphocyte blastogenesis by stimulation with
phytohemagglutinin (PHA).
PHA-P (Difco Laboratories, Detroit, U. S. A) at 5 pI was added. The culture
tubes were placed in an incubator with a 5% CO2atmosphere for 4 days. Six
hours before termination of culture, 0.5 pCi of 125I_UdR was added, and the
mixture was incubated. The culture tubes were centrifuged and the medium
was removed. The blood pellet was washed 3 times with normal saline. The
counting was performed by a well-type gamma counter in triplicate samples,
and the stimulation index was calculated.
RESULTS
All patients were treated according to the protocols for ANLL and ALL,
and individual cases were not affected much by the different chemotherapeutic
agents used in the follow-up study. In the ANLL group, the median durations
of complete remission and survival were 4 months and 8 months, respectively.
In the ALL group, the corresponding results were 6.5 months and 15 months,
respectively (Table 3).
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The results of the PPD test at different clinical stages are shown in Table 4.
A correlation was not apparent between PPD reactivity and clinical stages. Both
the ANLL and ALL group showed low ratios of positive reactivity. The DNCB
test results also showed the same tendencies in the ANLL and ALL group (Table
5).
TABLE 3. MEDIAN DURATIONS OF COMPLETE REMISSION AND SURVIVAL
IN ANLL AND ALL PATIENTS
No.of Median duration Median durationDiagnosis patients complete remission survival(mo.) (mo.)
-----------,-
ANLL 31 4 8 (range 1-21)
-----_ .. _-._--_._.
ALL 14- 6.5 15 (range 2-36)
------
TABLE 4. RESULTS OF PPD TEST IN DIFFERENT CLINICAL STAGES IN
ANLL AND ALL PATIENTS
Relapse
%
ALL clinical stage
PPD Test
ANLL clinical stage
Induction Complete
remission% %
Induction
%
Complete
remission
%
Relapse
%
Positive 35.5(8/30) 14.3(4/28) 10.0(2/20) 35.7(5/14) 46.2(6/13) 40.0(4/10)
Negative 64.5(22/30) 85.7(24/28) 90.0(18/20) 64.3(9/14) 53.8(7/13) 60.0(6/10)
~------c-------~--
Figures in parentheses represent the number of affected patient/total patient.
TABLE 5. RESULTS OF DNCB TEST IN ANLL AND ALL PATIENTS
DNCB Test ANLL ALL% %
Positive 35.7(5/14) 25.00/4)
-~,--,-- -- -------------------- -------
Negative 64.3(9/14) 75.0(3/4)
------
Figures in parentheses represent the number of affected patient/total patient.
The prognosis was compared against the cellular immunity findings at the
induction therapy stage. The survival curves of PPD positive and negative pa-
tients were drawn by actuarial method. In ANLL patients, the 50% median sur-
vival rate of the PPD positive group was 11 months after diagnosis and the PPD
negative group, 6 months after diagnosis (Fig. 2). In ALL patients, the values
were 21 months and 13 months, respectively, after diagnosis (Fig. 3). These
results suggest a tendency for longer survival of patients reacting positively at
the beginning of therapy in both the ANLL and ALL groups.
The results of lymphocyte blastogenesis in different clinical stages are shown
in Fig. 4 and Fig. 5. The lymphocyte blastogenesis stimulation index in normal
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Fig. 2. Actuarial curve of ANLL patients against
PPD reactivity. The PPD test: was conducted on ad-
mission.
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Fig. 3. Actuarial curve of ALL patients against PPD reactivity. The PPD test
was conducted on admission.
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Fig. 4. PHA-induced lymphocyte blastogenesis in different stages of ANLL
patients. The stimulation index was based on 125I-UdR incorporation rate. S.l,
stimulation index; m, mean; s, standard deviation; C. remission, complete re-
mission; control, normal individuals.
5
Toki et al.: The relationship of cellular immunity to prognosis in acute
Produced by The Berkeley Electronic Press, 1977
56 H. TOKI et at.
I
5.1.
Induction.-
o
mr'·----'-c
10
__-.:
2
=o'-----_-.:3=O'-----__4=-O
c. remission .To
Maintenance
Relapse
00
.0
m
. .-, -:. .
c [_. ~ 0 m s
_o_n_tr_o_1--..J -.; 1-\ •• ·:1- ~_"o_o_0_:0_"_1 _
Fig. 5. PHA-induced lymphocyte blastogenesis in different stages of ALL
patients. The stimulation index was based on 125I-UdR incorporation rate.
controls was 18.3 ± 9.1 (M ± S. D.). The stimulation indices during induction,
complete remission, maintenance and relapse were 10.2,10.7,10.9 and 11.1, re-
spectively, inANLL; and the values were 4.4,4.7,12.8 and 9.9, respectively,
in ALL. There was no correlation between lymphocyte blastogenesis and clini-
cal stages. Furthermore, these results did not introduce evidence of immuno-
competent recovery during stages of complete hematological remission.
DISCUSSION
This paper demonstrated that prognoses in acute leukemia and cellular im-
munity were closely related. It appears that prognosis may be more favorable
when cellular immunity in the induction phase is sufficiently preserved.
The PPD test on admission may aid in predicting prognosis. In Japan the
high incidence of PPD positive reactivity due to the widespread preventive use
of BeG vaccination places more importance in the evaluation of the PPD recall
antigen testing of cellular immunity compared with studies in Europe and the
United States, where the positive PPD reactivity incidence is low in the general
population.
The PHA-stimulated lymphocyte blastogenesis is considered to indicate T-
lymphocyte function in vitro and has a close correlation with delayed cutaneous
hypersensitivity (10). The microtechnique of using whole blood in the PHA test
has the advantage of reflecting the immunological reactivity of the patient, as
whole blood retains blood cells in natural proportions (11). For effective patient
cellular immunity against malignant cells, not only lymphocyte function but
total lymphocyte count is important. Therefore, the PHA test performed in this
study was useful for measuring the whole body response by active T -lympho-
cytes.
The median value in the PHA test of the ANLL group was slightly higher
than the value of the ALL group, and the cellular immunity of the ANLL group
may be thought to be better preserved than that of ALL. However, the present
study did not show a correlation between the PHA test and various clinical stages
of ANLL and ALL.
6
Acta Medica Okayama, Vol. 31 [1977], Iss. 1, Art. 4
http://escholarship.lib.okayama-u.ac.jp/amo/vol31/iss1/4
Cellular Immunity of Acute Leukemia 57
Hersh and Oppenheim (1) reported that lymphocyte function in Hodgkin's
disease was impaired and that the immunological response was related to the
severity of the disease. The same conclusions were reported by several other
researchers (2-4), although some data were inconsistent on the correlation be-
tween lymphocyte blastogenesis and disease severity (12, 13). In metastatic
solid tumors and lung cancers, immunological studies have supported the concept
of a correlation between cellular immunity and clinical course (5, 14).
Depuy et at. (6) showed that in acute leukemia the abolition of delayed
hypersensitivity reactions occurring during drug-induced aplasias correlated with
the severity of the aplasia and that the delayed hypersensitivity reactions were
slightly impaired before treatment. Hersh et at. (7) reported that acute leukemia
patients converting from immunoincompetence to immunocompetence during
therapy achieved remission and that cell-mediated immunity correlated with the
response to chemotherapy. Furthermore, the data of Green and Borella (15) in
acute lymphocytic leukemia demonstrated immunological rebound after cessa-
tion of long-term chemotherapy.
In summary, the reviewed literature and our studies suggested that in acute
leukemia prognosis and cellular immunity may be related. It may be further
suggested that the cellular immunocomponent function by T -lymphocytes may
help to eliminate residual leukemic cells after anti-leukemic drugs are adminis-
tered to rapidly reduce the mass of leukemic cells. In this respect, T -lymphocyte
function as a possible routine indicator of the clinical condition and prognosis in
leukemia needs continued and further evaluation.
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